ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1232

Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?

Glenn Haugeberg1, Torhild Garen2, Hege Sommerseth3, Anne Prøven3 and Knut Helgetveit3, 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 2Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 3Rheumatology, Martina Hansens Hospital, Bærum, Norway

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologic agents, Dual energy x-ray absorptiometry (DEXA), longitudinal studies, Osteoporosis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to be superior to synthetic DMARDs to reduce bone destruction including generalized bone loss. Our aim was primarily to study short- and long term changes in bone mineral density (BMD) at hip and lumbar spine in patients with early RA followed in the biologic treatment era.

Methods: RA patients with early disease diagnosed at an out-patient clinic between 1999 and 2001 were consecutively enrolled in the study. Demographic, disease and treatment data were collected at standard visits. Dual energy X-ray absorptiometry at hip and spine L1-4 was performed at baseline and after 2, 5 and 10 years.

Results: At baseline mean age (SD) in the 92 RA patients was 50.9 (13.3) years, symptom duration 12.4 (6.7) months, 62.0% were women, 66.3% were RF positive and 65.9%% were CCP positive. In the first 2 years ever use of biologic DMARDs was 18.5%, synthetic DMARDs 91.3% and prednisolone 62.0% whereas the figures for the subsequent 8 years were 62.6%, 51.4% and 89.2%, respectively. Baseline, mean values for 0-2 years and 2-10 years follow up was for ESR mm/hr 30 (21), 21 (12) and 13 (7), for CRP mg/dl 29 (34), 19 (15) and 8 (7), for DAS28 5.2, 4.2 and 2.9 and for MHAQ 0.68 (0.51), 0.42 (0.30) and 0.27 (0.27). 

The annual rate of BMD loss in the first 2 years and in the subsequent 8 years was at femoral neck -1.00% vs. -0.56%, at total hip -0.96% vs. -0.41% and at spine L1-4 -0.42% vs. 0.00%. The corresponding figures at femoral neck, total hip and spine L1-4 were in men -0.89% vs. -0.29%, -1.01% vs. -0.07% and -0.20% vs. 0.76%, in pre-menopausal women -0.93% vs. -0.39%, -1.20% vs. -0.11% and -0.42% vs. -0.06% and in post-menopausal women -0.75% vs. -0.91%, -0.74% vs. -0.85% and -0.49% vs. -0.61%.

Conclusion: Our study adds evidence that aggressive anti-inflammatory treatment in particular with biologics reduces the rate of bone loss in RA down to a level reported in the general population.


Disclosure:

G. Haugeberg,
None;

T. Garen,
None;

H. Sommerseth,
None;

A. Prøven,
None;

K. Helgetveit,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoporosis-in-rheumatoid-arthritis-still-a-threat-in-the-biologic-era/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology